Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules.
A lipophilic immunomodulator (MTP-Chol) was included in nanocapsules prepared from different polymers and the anti-metastatic effects of the resulting drug delivery systems were evaluated in a murine model of liver metastases. Loaded nanocapsules were effective if they were given 2 days before tumor inoculation. Neither the nature of the polymer nor the total dose of immunomodulator affected the antimetastatic capacity. However, enhanced anti-metastatic activity was obtained when indomethacin nanocapsules were associated with MTP-Chol nanocapsules. These results show that nanocapsules containing an immunomodulator possess anti-metastatic activity, but only when given as a prophylactic treatment; this would correspond, in the clinic, to patients undergoing surgery for a primary tumor and at risk of developing liver metastases.
Barratt
G
G
URA CNRS 1218, Physico-Chimie, Pharmacotechnie, Biopharmacie, Université de Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France.
Puisieux
F
F
Yu
W P
WP
Foucher
C
C
Fessi
H
H
Devissaguet
J P
JP
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002214:Capsules; D002784:Cholesterol / Q000008:administration & dosage*; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control* / Q000556:secondary*; D051379:Mice; D011108:Polymers / Q000008:administration & dosage
D000970:Antineoplastic Agents; D002214:Capsules; D011108:Polymers; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C035104:muramylNAc-Ala-isoGln-Lys-tripeptide; D002784:Cholesterol